Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
CAMBRIDGE, Mass., March 13, 2018 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the 17th Annual Needham Healthcare Conference in New York, New York on Wednesday, March 28, 2018 at 9:00am Eastern Time.
The presentation will be live webcast at: http://wsw.com/webcast/needham86/vcel, and may be accessed from the news and events section of the Vericel website.
About Vericel Corporation
Vericel is a leader in advanced cell therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. For more information, please visit the company's website at www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel Corporation. © 2018 Vericel Corporation. All rights reserved.
(vcel-corp)
Global Media Contacts:
David Schull
Russo Partners LLC
+1 212-845-4271 (office)
+1 858-717-2310 (mobile)
[email protected]
Karen Chase
Russo Partners LLC
+1 646-942-5627 (office)
+1 917-547-0434 (mobile)
[email protected]
Investor Contacts:
Chad Rubin
The Trout Group
[email protected]
+1 (646) 378-2947
Lee Stern
The Trout Group
[email protected]
+1 (646) 378-2922
